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Abstract 
A thin-layer chromatographic method for simultaneous determination of moxonidine and 
its four impurities was developed and validated. Separation of the examined compounds 
was performed on chromatographic plates precoated with silica gel 60 F254 and using 
methanol-toluene-dichloroethane-ammonia 2:3:3:0.1 (v/v/v/v) as mobile phase. 
Ascending development mode was performed in the twin-trough chromatographic 
chamber, which was presaturated with mobile phase vapors for 15 min. The developed 
chromatographic plates were dried in air and densitometrically scanned at the 
wavelengths 260 and 280 nm. Regression coefficients (r ≥ 0.998), recovery (90.10 % - 
107.63 % ), LOQ  of impurities (20 ng band
-1
 equivalent to the 0.12 % impurity level) 
and robustness were validated and found satisfactory. The developed method is well 
suited for quantitative analysis and purity control of moxonidine in its dosage forms. 
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INTRODUCTION 
Moxonidine as a centrally active I1 receptor agonist with minor activity at 2-
adrenoceptors has been extensively used in treatment of hypertension. Moreover, 
moxonidine improves metabolic profile of patients with hypertension and the type 2 
diabetes, or with an impaired glucose tolerance.
[1,2]
 
 
Moxonidine belongs to the second generation of imidazoline compounds and some 
theoretical studies have been performed on physicochemical properties of a series of 
structurally similar drugs acting on the I1 and α2-adrenoceptors.
[3,4]
 Lipophilicity and 
acidity of moxonidine, and those of structurally similar imidazolines and oxazolines have 
been evaluated with aid of different separation techniques such, as high performance 
liquid chromatography (HPLC)
[5]
 and thin layer chromatography (TLC).
[6,7] 
This 
evaluation was based on measuring of retention behavior of the compounds of interest in 
the employed separation systems. Several reports are available describing determination 
of moxonidine in human plasma by means of liquid chromatography-electrospray 
ionization-mass spectrometry (LC-ESI-MS)
[8]
 and gas chromatography-mass 
spectrometry (GC-MS).
[9]
 
 
According to European Pharmacopoeia (EP)
[10]
 and British Pharmacopoeia (BP),
[11] 
determination of moxonidine and its four related substances is based on HPLC. Recently, 
the HPLC method 
[12]
 was developed and validated for the determination of moxonidine 
in the presence of its impurities, and the UPLC method
[13]
 was devised as a stability 
indicating method for the determination of moxonidine and its degradation products in 
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pharmaceuticals. Hydrophilic interaction chromatography (HILIC) devised for the 
separation of moxonidine in the presence of five related compounds is an alternative to 
the reversed-phase (RP) HPLC for determination of polar analytes in a pharmaceutical 
matrix.
[14] 
 
The EP monograph of moxonidine in the section referring to the related substances 
focuses on the two process-related impurities only, i.e., impurity A (6-chloromoxonidine) 
and impurity B (4-metoxymoxonidine), whereas further two impurities, C (4-
hydroxymoxonidine) and D (6-desmethylmoxonidine), are classified as other impurities. 
Structures of moxonidine and its impurities are shown in Fig. 1. The impurity types and 
ratios differ depending on the reaction conditions. Position C(4)/C(6) of the pyrimidine 
moiety is reactive to nucleophilic substitution.
[15]
 Even a low level of humidity or the 
presence of other nucleophiles which might originate from different sources (such, as the 
tablet matrix/excipients) can affect the stability of moxonidine and generate impurities. A 
stability indicating high performance thin-layer chromatographic method was reported 
and validated for analytical estimation of moxonidine in the presences of the degradants, 
excipients and impurities. Structure of the impurities was not elucidated.
[16.]
 
 
Except for the aforementioned reports,
[12,13]
 there is still, however, a limited information 
on an assessment of the moxonidine purity in pharmaceuticals. This prompted us to 
develop and validate an alternative TLC method for the simultaneous determination of 
moxonidine and its impurities using instrumental planar chromatography. 
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EXPERIMENTAL 
Materials 
Moxonidine, 4-chloro-N-(imidazolidin-2-ylidene)-6-methoxy-2-methylpyrimidin-5-
amine; Impurity A, 4,6-dichloro-N-(imidazolidin-2-ylidene)-2-methylpyrimidin-5-amine 
(6-chloromoxonidine); Impurity B, N-(imidazolidin-2-ylidene)-4,6-dimethoxy-2- 
methylpyrimidin-5-amine (4-methoxymoxonidine); Impurity C, 5-[(imidazolidin-2-
ylidene)amino]-6-methoxy-2-methylpyrimidin-4-ol (4-hydroxymoxonidine,); and 
Impurity D, 6-chloro-5-[(imidazolidin-2-ylidene)amino]-2-methylpyrimidin-4-ol (6 
desmethylmoxonidine) were obtained from Chemagis (Bnei Brak, Israel). The 
Moxogamma
®
 0.4 mg filmtablets were manufactured by Worwag Pharma 
(Böblingen,Germany). 
 
Lactosa monohydrate, povidone K-25, crospovidone, and magnesium stearate were of the 
EP quality and used for the preparation of the placebo mixture. All other reagents, i.e., 
toluene (POCH, Gliwice, Poland), 1,2 dichloroethane (Fisher Chemical, Loughborough, 
UK), ammonia solution 25% (Merck, Darmstadt,Germany) and methanol (Merck, 
Darmstadt, Germany) were of analytical purity. 
 
Solutions 
Standard Solutions 
Stock solutions for moxonidine (1 mg mL
-1
) and impurities A, B, C and D (0.2 mg mL
-1
) 
were prepared in methanol. For the calibration curves, six different solutions were 
  5 
prepared by diluting the stock solutions in the concentration range from 0.2 to 0.6 mg 
mL
-1 
for moxonidine and 0.02 to 0.2 mg mL
-1 
for impurities A, B, C and D. 
 
Sample Solutions 
Ten tablets from which the film was previously removed were weighed and pulverized. 
The quantity of the powdered tablets equivalent to 2.0 mg moxonidine was transferred to 
the 5 mL volumetric flask and sonicated in 4 mL methanol for 20 min, using an 
ultrasonic bath. The solution was made up to 5 mL with the same solvent, and then 
centrifuged at 3000 U/min for 15 min. The obtained supernatant was filtered through the 
0.45 mm pore size membrane filter (Millipore). For an assay of moxonidine and the 
impurities, the 1-µL and 40-µL aliquots of the filtrates, respectively, were applied to the 
chromatographic plates.  
 
Chromatography 
TLC was performed on the 20 cm  10 cm plates cut from the 20 cm  20 cm aluminium 
backed plates, precoated with silica gel 60 F254 (Merck, Darmstadt, Germany). 
 
Standard and sample solutions were applied 10 mm above the lower edge of the plate, 
using the Linomat 5 (Camag Muttenz, Switzerland) application device. Samples were 
applied band-wise with the 10 mm band width, with an application rate of 100 nL s
-1
. 
Ascending development mode at ambient temperature was performed to the distance of 
95 mm in the twin-trough TLC chamber presaturated with mobile phase (methanol-
toluene-dichloroethane-ammonia, 2:3:3:0.1 (v/v/v/v)) for 15 min. After the development, 
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the chromatographic plates were dried for 30 minutes at ambient air and once again 
developed to the distance of 95 mm in the freshly prepared mobile phase of the same 
composition as before, after 15 min chamber presaturation. Dried chromatographic plates 
were scanned at the wavelengths of 280 and 260 nm by means of the Camag TLC 
Scanner II in the reflectance/absorbance mode. 
 
RESULTS AND DISCUSSION 
In order to optimize chromatographic conditions for an efficient separation of 
moxonidine and its four impurities, different stationary phases and different mobile phase 
compositions were examined. Preliminary studies have started from examination of the 
retention behavior of the analytes using single nonpolar (toluene) and single polar 
(methanol) solvent as two monocomponent mobile phases, and the polar silica gel plates 
as stationary phase. 
 
In contrast to the retention behavior in nonpolar solvents (such, as toluen), where all 
analytes demonstrated high affinity toward stationary phase and were retained on the start 
line, higher mobility (especially with moxonidine) was observed with use of a polar 
solvent (such, as methanol). In order to achieve satisfactory resolution of the examined 
compounds, further tests were directed toward examination of the analytes' retention in 
the toluene-methanol mixture. In order to reduce peak tailing, basic solvent (ammonia, or 
triethylamine (TEA)) was added to mobile phase . Higher volume fraction of methanol in 
mobile phase resulted in a too high Rf value for moxonidine and impurity A, while 
impurities B, C and D were retained close to the start line. Therefore, higher proportion 
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of toluen was selected, which significantly reduced the Rf values for moxonidine and 
increased resolution among the tested compounds. Different volume ratios of methanol, 
toluen and TEA were tested to optimize the mobile phase composition and in the course 
of these experiments, considerable difference in the retention behavior was observed 
between impurity C and impurity A. In fact, impurity C remained close to the start line, 
while impurity A migrated close to the front line. 
 
Well separated and compact zones were obtained by adding dichloroethane to the eluent 
mixture and the next qualitative and quantitative mobile phase composition was assumed 
as methanol-toluene-dichloroethane-TEA, 2:3:3:0.1, v/v/v/v. In that case, the migration 
distances (MD ± RSD) for moxonidine and impurities A, B, C and D were equal, 
respectively, to 41.2 mm ± 0.99 %, 51.9 mm ± 0.82 %, 24.2 mm ± 0.40 %, 13.6 mm ± 
0.87 %, and 19.4 mm ± 0.74 %. Later it was noticed that impurities C and A co-eluted 
with the tablet matrix, which was finally avoided by replacing TEA with an equal volume 
proportion of ammonia and assuming double development of the chromatogram using the 
same mobile phase, methanol-toluen-dichloroethane-ammonia 2:3:3:0.1, v/v/v/v. Thereby 
the method specificity was achieved and the migration distances for moxonidine and 
impurities A, B, C and D were: 58.5 mm ± 0.78 %, 64.4 mm ± 0.95 %, 34.5 mm ± 0.56 
%, 16.1 mm ± 0.68 %, and 25.6 mm ± 0.85 %. 
 
Retention order of the separated substances (C>D>B>moxonidine>A) is basically driven 
by structural characteristics of the C4/6 pirimidine moiety present in the investigated 
compounds and by an ability of these compounds to form hydrogen bonds with the 
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siloxane and silanol groups of silica gel. Similar elution order of moxonidine and its 
impurities was observed in the polar HILIC HPLC system
.
,
[14]
 with one exception only 
for the reverse order of D and C (D>C>B>moxonidine>A). 
 
Testing the elaborated mobile phase composition upon the HPTLC and HPTLC 
LiChrospher Si60 plates, no better resolutions was achieved, so that the aluminium 
backed chromatographic plates precoated with silica gel 60 F254 were used for further 
validation of the developed TLC method. 
 
For moxonidine and impurities A, C and D, quantitative measurements were performed at 
the wavelength 280 nm, and for impurity B, at the the wavelength 260 nm. The 
relationship between the peak area and the amount of the applied substance was 
evaluated with use of the linear and the second degree polynomial regression functions. 
Fitting with the second-degree polynomial was done because a wider concentration range 
is required for quantification of an impurity in the purity method. The obtained regression 
data are summarized in Table 1. 
 
To avoid systematic errors, an effect of larger amounts of moxonidine on the peak shape 
and resolution of impurities had to be tested. Method accuracy was therefore verified by 
determination of impurities A, B, C and D in the presence of moxonidine. The 
laboratory-made placebos were spiked with moxonidine and a mixture of 0.3, 0.5, and 1.2 
% impurities A, B, C and D, respectively. The application volumes were 40-µL and 20-
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µL for the estimation of 0.3, 0.5 and 1.2 % impurities, respectively. Scanned profiles 
obtained for the moxonidine samples spiked with impurities are presented in Fig. 2. 
 
Calculated recoveries were plotted against the expected values (corresponding to the 
standards without moxonidine). Recoveries and the relative standard deviation (RSD) 
values for all impurities was acceptable for the purity method (Table 2). Repeatability of 
the method was evaluated by chromatographic replicate applications (n=6) of moxonidine 
and impurities A, B, C and D at three different concentrations. Statistical data obtained 
from these experiments are given in Table 3. 
 
The limit of detection (LOD) and the limit of quantification (LOQ) values were obtained 
experimentally and statistically. Experimentally obtained LOD values for impurities A, 
B, C and D were equal to 7 ng per band, while experimentally obtained LOQ values were 
equal to 20 ng per band (corresponding with the impurity levels of 0.04 % and 0.12 %, 
respectively). Statistically, the LOD values were determined by fitting the interday back-
calculated standard deviation for each calibration standard. The y-intercept was then 
equal to SD0 (the estimated standard deviation at zero concentration). LOD was defined 
as 3SD0 and LOQ as 10SD0. The LOD values obtained for impurities A, B, C and D were 
8.41 ng, 7.89 ng, 7.32 ng, and 3.73 ng, respectively (equivalent to the impurity levels of 
0.053 %, 0.049 %, 0.046 %, and 0.023 %, respectively). The LOQ values for impurities 
A, B, C and D were 28.00 ng, 26.30 ng, 24.41 ng, and 12,43 ng, respectively (equivalent 
to the impurity levels of 0.175 %, 0.164 %, 0.153 %, and 0.078 %, respectively).  
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Robustness is a measure of the capacity of the method to remain unaffected by small yet 
deliberate variations of working conditions, and it is indicative of the method 
reliability.
[17]
 In the robustness test, the effects of different amounts of methanol in 
mobile phase (± 5%), different developing distances (90 and 98 mm), different spot band 
sizes (6 and 8 mm), and different chamber geometry (twin-trough and flat) were 
examined. Selection of the tested factors was based on our experience and observations 
made in the course of method development. Based on the obtained results, no observable 
effects on resolution between moxonidine and its impurities was perceived, showing that 
the proposed method remains unafected by small yet deliberate variations of the working 
conditions. 
 
The method was used to screen the commercial dosage forms. The densitogram obtained 
for moxonidine and the impurity standards is shown in Fig. 3. No intereference of tablet 
formulation was observed using the developed chromatographic system, which confirms 
good selectivity of the method. The results obtained for the content of moxonidine of 
97.41 % and the found levels of impurities C and D of 0.21 % and 0.26 %, respectively, 
meet the requirements of the manufacturer, and do not exceeded 1.0 %. The contents of 
impurities D and A were established as lower than LOD of the proposed method. (Table 
4). 
 
CONCLUSION 
In spite of the fact that the number of TLC application is steadily decreasing, replaced by 
the HPLC methods,
[18]
 the obtained results show that instrumental planar chromatography 
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is powerful enough to be used for the purity testing of the low dosage units (as it is the 
case with 0.4 mg moxonidine per tablet) and it is well suited as an alternative method for 
the drug quality control. 
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TABLE 1. Statistical Data for the Calibration Curves-Calibration Function y = a + bx + 
cx
2 
Compound Concentration 
range            
[ng band
-1
] 
a b c SD r 
Moxonidine 200-600 -22.83 ± 
10.67 
0.90 ± 
0.06 
1.24E-04 ± 
6.42 E-05 
4.306 0.999 
Impurity A 20-200 77.66 ± 
12.49 
3.45 ± 
0.29 
-9.53E-04 ± 
0.001 
9.680 0.998 
Impurity B 20-200 13.41 ± 
32.15 
8.06 ± 
0.89 
-0.007 ± 0.005 21.199 0.998 
Impurity C 20-200 10.44 ± 
16.86 
5.35 ± 
0.40 
-0.003 ± 0.002 13.062 0.999 
Impurity D 20-200 18.77 ± 
7.62 
4.75 ± 
0.18 
-0.004 ± 8.09E-
04 
5.906 0.999 
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TABLE 2. Accuracy of the Method 
Compound Level 
[%] 
Mean Recovery [%] RSD [%] 
Moxonidine 80 99.52 1.38 
100   100.36 0.89 
                        
120 
99.81 0.95 
Impurity A 0.3 103.28 5.89 
0.5 107.63 2.20 
1.2 101.07 2.37 
Impurity B 0.3 98.29 2.48 
0.5 104.40 4.25 
1.2 97.87 2.06 
Impurity C 0.3 100.37 2.96 
0.5 93.95 3.84 
1.2 90.10 3.87 
Impurity D 0.3 95.84 1.78 
0.5 101.76 3.76 
1.2 95.66 2.07 
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TABLE 3. Precision of the Method (n=6) 
Amount [ng 
band
-1
] 
Moxonidine 
RSD [%] 
Impurity A 
RSD [%] 
Impurity B 
RSD [%] 
Impurity C 
RSD [%] 
Impurity D 
RSD [%] 
200 1.00     
400 0.74     
600 0.68     
50  2.32 3.89 3.74 2.71 
80  1.40 2.63 1.44 1.75 
190  1.81 1.50 1.29 1.19 
 
 
 
 
 
  17 
TABLE 4. Assay of Moxonidine and Its Impurities 
Sample Moxonidine 
[% ± RSD] 
Impurity 
A [% ± 
RSD] 
Impurity B 
[% ± RSD] 
Impurity C 
[% ± RSD] 
Impurity D 
[% ± RSD] 
Moxogamma
®
 0.4 mg 97.41 ± 1.92 n.d. n.d. 0.21 ± 6.87 0.26 ± 4.82 
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Figure 1. Chemical structures of moxonidine and its impurities 
 
  19 
Figure 2. Densitograms obtained at the wavelength 280 nm for (a) sample of placebo; 
(b,d,f) standards of impurities A, B, C and D at 0.3 %, 0.5 % and 1.2 % level (peaks 4, 3, 
1 and 2, respectively); (c,e,g) placebo spiked with moxonidine and impurities A, B, C and 
D at 0.3 %, 0.5 % and 1.2 % level (peaks 5, 4, 3, 1 and 2, respectively). 
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Figure 3. Densitogram obtained at the wavelength 280 nm for (a) sample of placebo; 
(b,c) samples of the moxonidine tablet; (d) standards of impurities A, B, C and D at 0.3 
% level (peaks 4, 3, 1 and 2, respectively); (e) standards of impurities A, B, C and D at 
0.5 % level (peaks 4, 3, 1 and 2, respectively). 
 
 
